Terms: = Kidney tumors AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Prognosis
80 results:
1. MAEL in human cancers and implications in prognostication and predicting benefit from immunotherapy over vegfr/mTOR inhibitors in clear cell renal cell carcinoma: a bioinformatic analysis.
Tao J; Cui J; Xu Y; Fan Y; Hong G; Zhou Q; Wang G; Li L; Han Y; Xu C; Wang W; Cai S; Zhang X
Aging (Albany NY); 2024 Jan; 16(3):2090-2122. PubMed ID: 38301040
[No Abstract] [Full Text] [Related]
2. Leveraging diverse cell-death related signature predicts the prognosis and immunotherapy response in renal clear cell carcinoma.
Wu Z; Jin M; Xin P; Zhang H
Front Immunol; 2023; 14():1293729. PubMed ID: 38146369
[TBL] [Abstract] [Full Text] [Related]
3. kidney-type glutaminase is a biomarker for the diagnosis and prognosis of hepatocellular carcinoma: a prospective study.
Zhang L; Su K; Liu Q; Li B; Wang Y; Cheng C; Li Y; Xu C; Chen J; Wu H; Zhu M; Mai X; Cao Y; Peng J; Yue Y; Ding Y; Yu D
BMC Cancer; 2023 Nov; 23(1):1081. PubMed ID: 37946141
[TBL] [Abstract] [Full Text] [Related]
4. Endothelial vegfr2-PLCγ signaling regulates vascular permeability and antitumor immunity through eNOS/Src.
Sjöberg E; Melssen M; Richards M; Ding Y; Chanoca C; Chen D; Nwadozi E; Pal S; Love DT; Ninchoji T; Shibuya M; Simons M; Dimberg A; Claesson-Welsh L
J Clin Invest; 2023 Oct; 133(20):. PubMed ID: 37651195
[TBL] [Abstract] [Full Text] [Related]
5. 2023 ASCO genitourinary cancers symposium: focus on renal cell carcinoma.
Anghelone A; Strusi A; Scala A; Panebianco M; Ciccarese C; Iacovelli R
Expert Rev Anticancer Ther; 2023 Jul; 23(7):669-672. PubMed ID: 37246571
[TBL] [Abstract] [Full Text] [Related]
6. Does red blood cell distribution width predict prognosis in metastatic renal cell carcinoma patients using first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy?
Korkmaz M; Eryılmaz MK; Koçak MZ; Er MM; Hendem E; Demirkıran A; Araz M; Karaağaç M; Artaç M
J Cancer Res Ther; 2023 Apr; 19(Supplement):S0. PubMed ID: 37147975
[TBL] [Abstract] [Full Text] [Related]
7. Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/vegfr therapy: real-life evidence on the change of the treatment paradigm.
Bamias A; Zakopoulou R; Tzannis K; Sakellakis M; Koutsoukos K; Kyriazoglou A; Panagiotou A; Armylagos S; Rokas K; Gotzias D; Boulouta A; Bozionelou V; Stravodimos K; Varkarakis I; Mavroudis D; Dimopoulos MA
Anticancer Drugs; 2023 Mar; 34(3):413-421. PubMed ID: 36730619
[TBL] [Abstract] [Full Text] [Related]
8. Clinical impact of early response to first-line vegfr-TKI in patients with metastatic renal cell carcinoma on survival: A multi-institutional retrospective study.
Sobu R; Numakura K; Naito S; Hatakeyama S; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Arai Y; Ito A; Nishiyama H; Kojima Y; Obara W; Ohyama C; Tsuchiya N; Habuchi T
Cancer Med; 2023 Feb; 12(4):4100-4109. PubMed ID: 36200612
[TBL] [Abstract] [Full Text] [Related]
9. Calbindin S100A16 Promotes Renal Cell Carcinoma Progression and Angiogenesis via the VEGF/vegfr2 Signaling Pathway.
Wang N; Wang R; Tang J; Gao J; Fang Z; Zhang M; Shen X; Lu L; Chen Y
Contrast Media Mol Imaging; 2022; 2022():5602011. PubMed ID: 36176934
[TBL] [Abstract] [Full Text] [Related]
10. Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma.
Colomba E; Alves Costa Silva C; Le Teuff G; Elmawieh J; Afonso D; Benchimol-Zouari A; Guida A; Derosa L; Flippot R; Raynard B; Escudier B; Bidault F; Albiges L
J Cachexia Sarcopenia Muscle; 2022 Oct; 13(5):2405-2416. PubMed ID: 35903892
[TBL] [Abstract] [Full Text] [Related]
11. Tivozanib for the treatment of advanced renal cell carcinoma.
Chatzkel J; Ramnaraign B; Sonpavde G
Expert Opin Pharmacother; 2022 Jul; 23(10):1135-1142. PubMed ID: 35848061
[TBL] [Abstract] [Full Text] [Related]
12. Tivozanib: A New Hope for Treating Renal Cell Carcinoma.
Passi I; Billowria K; Kumar B; Chawla PA
Anticancer Agents Med Chem; 2023; 23(5):562-570. PubMed ID: 35718972
[TBL] [Abstract] [Full Text] [Related]
13. Integrative Analysis of the Genomic and Immune Microenvironment Characteristics Associated With Clear Cell Renal Cell Carcinoma Progression: Implications for prognosis and Immunotherapy.
Lin E; Zhu P; Ye C; Huang M; Liu X; Tian K; Tang Y; Zeng J; Cheng S; Liu J; Liu Y; Yu Y
Front Immunol; 2022; 13():830220. PubMed ID: 35677048
[TBL] [Abstract] [Full Text] [Related]
14. DMDRMR promotes angiogenesis via antagonizing DAB2IP in clear cell renal cell carcinoma.
Zhu Y; Liu X; Wang Y; Pan Y; Han X; Peng B; Zhang X; Niu S; Wang H; Ye Q; Gu Y; Gao S
Cell Death Dis; 2022 May; 13(5):456. PubMed ID: 35562342
[TBL] [Abstract] [Full Text] [Related]
15. Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.
Oya M; Kaneko S; Imai T; Tsujino T; Sunaya T; Okayama Y
Cancer Chemother Pharmacol; 2022 Jun; 89(6):761-772. PubMed ID: 35445315
[TBL] [Abstract] [Full Text] [Related]
16. Systemic Therapy in Patients With Metastatic Xp11.2 Translocation Renal Cell Carcinoma.
Yan X; Zhou L; Li S; Wu X; Cui C; Chi Z; Si L; Kong Y; Tang B; Li C; Mao L; Wang X; Lian B; Bai X; Dai J; Guo J; Sheng X
Clin Genitourin Cancer; 2022 Aug; 20(4):354-362. PubMed ID: 35387755
[TBL] [Abstract] [Full Text] [Related]
17. Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients.
Jiang W; Zeng H; Liu Z; Jin K; Hu B; Chang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
Urol Oncol; 2022 Apr; 40(4):166.e15-166.e25. PubMed ID: 34998671
[TBL] [Abstract] [Full Text] [Related]
18. [Interdisciplinary recommendations for the treatment of advanced renal cell carcinoma].
Miller K; Bergmann L; Doehn C; Grünwald V; Gschwend JE; Ivanyi P; Kuczyk MA
Aktuelle Urol; 2022 Sep; 53(5):403-415. PubMed ID: 34852368
[TBL] [Abstract] [Full Text] [Related]
19. Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16).
Basso U; Procopio G; Fornarini G; Massari F; Bearz A; Fratino L; Milella M; Bassanelli M; Ermacora P; Bimbatti D; Verzoni E; Rizzo M; Porta C
Oncology; 2021; 99(12):747-755. PubMed ID: 34583356
[TBL] [Abstract] [Full Text] [Related]
20. Efficacy of vegfr-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis.
Ciccarese C; Iacovelli R; Porta C; Procopio G; Bria E; Astore S; Cannella MA; Tortora G
Cancer Treat Rev; 2021 Nov; 100():102295. PubMed ID: 34564043
[TBL] [Abstract] [Full Text] [Related]
[Next]
